ARCT - Arcturus Therapeutics lose a third in postmarket after vaccine data update

Arcturus Therapeutics (ARCT) is down 35.0% in after-hours as the company provided the clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021. Arcturus also announced that the Singapore Health Sciences Authority has signed off its Phase 2 clinical study backed by favorable Phase 1/2 study results, as well as supportive preclinical data.Of the 106 participants in the Phase 1/2 trial, 78 received ARCT-021; 28 received placebo. 44 subjects have received ARCT-021 at doses selected for Phase 2 (27 young adults and 17 older adults). Two groups of 34 and 10 participants have each received a single administration of 5 µg and 7.5 µg, respectively, and a group of 24 participants has received a prime-boost regimen (5 µg x 2).Only serious adverse event was in a placebo participant. Two subjects had mild or moderate adverse events at doses selected for Phase 2: Transient, asymptomatic Grade 3 lymphopenia, and in one older adult - transient Grade

For further details see:

Arcturus Therapeutics lose a third in postmarket after vaccine data update